Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
tisotumab vedotin × 90 days × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03485209 2026-04-20

innovaTV 207

Seagen Inc.

Phase 2 Active not recruiting
350 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Seagen Inc.

Phase 1/2 Terminated
214 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡